2-methyl-3-ethyl-1,4-dihydroxynaphthalene | 38262-45-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-methyl-3-ethyl-1,4-dihydroxynaphthalene
• 英文别名: 2-Ethyl-3-methylnaphthalene-1,4-diol
• CAS: 38262-45-2
• 化学式: C₁₃H₁₄O₂
• 分子量: 202.253
• InChiKey: IZKJOVONCILCNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-3-ethyl-1,4-dihydroxynaphthalene 、 乙酸酐 生成 1,4-diacetoxy-2-ethyl-3-methyl-naphthalene
  参考文献：
  名称：

  ALBEROLA, A.;GONZALEZ, NOGAL, A. M.;MARTINEZ, DE, ILARDUYA, J. A, AN. QUIM. PUBL. REAL SOC. ESP. FIS. Y QUIM., 1980, 76, N 2, 123-126

  摘要：

  DOI：
• 作为产物：
  描述：

  甲萘醌 、 三乙基铝 以17%的产率得到
  参考文献：
  名称：

  ALBEROLA, A.;GONZALEZ, NOGAL, A. M.;MARTINEZ, DE, ILARDUYA, J. A, AN. QUIM. PUBL. REAL SOC. ESP. FIS. Y QUIM., 1980, 76, N 2, 123-126

  摘要：

  DOI：

文献信息

• Naphtalene anti-psoriatic agents
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0282006A1

  公开（公告）日：1988-09-14

  Psoriasis in mammals is relieved by administering naphthalenes of the formula: wherein:     R¹ is lower alkoxy or optionally substituted phenoxy;     R² is hydrogen, lower alkyl, lower alkoxy, optionally substituted phenyl, optionally substituted phenoxy or optionally substituted phenylalkyl;     R³ is hydrogen, lower alkyl, lower alkoxy, halo, optionally substituted phenyl, optionally substituted phenyl-lower-alkyl or optionally substituted phenyl-lower-­alkoxy, and m is 1 or 2;     X and Y may be different or are the same, and if different are either R⁴ or -C(O)W, and if the same are both -C(O)W, wherein     R⁴ is lower alkyl or optionally substituted phenyl-lower-alkyl;     W is -OR⁵ or -NR⁶R⁷,     wherein R⁵ is alkyl, optionally substituted phenyl or optionally substituted benzyl; and R⁶ and R⁷ are independently hydrogen, lower alkyl, cycloalkyl or optionally substituted phenyl.

  哺乳动物的牛皮癣可通过服用式中的萘来缓解： 其中 R¹ 是低级烷氧基或任选取代的苯氧基； R² 是氢、低级烷基、低级烷氧基、任选取代的苯基、任选取代的苯氧基或任选取代的苯基烷基； R³ 是氢、低级烷基、低级烷氧基、卤代、任选取代的苯基、任选取代的苯基-低级烷基或任选取代的苯基-低级烷氧基，且 m 是 1 或 2； X 和 Y 可以不同或相同，如果不同，则为 R⁴ 或 -C(O)W，如果相同，则均为 -C(O)W、 其中 R⁴ 是低级烷基或任选取代的苯基-低级烷基； W 是-OR⁵或-NR⁶R⁷、 其中 R⁵ 是烷基、任选取代的苯基或任选取代的苄基；以及 R⁶ 和 R⁷ 独立地为氢、低级烷基、环烷基或任选取代的苯基。
• Menaquinol compositions and methods of treatment
  申请人：Epizon Pharma, Inc.

  公开号：US10822295B2

  公开（公告）日：2020-11-03

  The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use. Also disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of a menaquinol compound as disclosed above, or a mixture thereof, and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of a condition associated with vitamin K selected from for the treatment of osteoporosis and arteriosclerosis.

  本申请公开了高效制备高纯度式 I 化合物的方法及其使用方法。 本文还公开了药物组合物，该组合物包含治疗有效量的如上所述的孟喹醇化合物或其混合物，以及药学上可接受的赋形剂，其中该组合物对治疗与维生素 K 有关的病症有效，这些病症选自骨质疏松症和动脉硬化。
• Methods and compositions for preventing or treating tissue calcification
  申请人：Epizon Pharma, Inc.

  公开号：US10874623B2

  公开（公告）日：2020-12-29

  The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.

  本发明提供了预防或治疗（例如，减缓进展、阻止和/或逆转）有需要的受试者的组织钙化的方法和组合物，更具体地说，本发明涉及使用脑醌-7（MK-7）和/或脑醌-7（MKH2-7）预防或治疗（例如，减缓进展、阻止和/或逆转）糖尿病、慢性肾病、终末期肾衰竭或接受血液透析和/或接受抗凝血治疗的受试者的组织钙化的方法、本发明涉及使用月桂醌-7（MK-7）和/或月桂醌醇-7（MKH2-7）预防或治疗（例如，减缓、阻止和/或逆转）糖尿病、慢性肾病、终末期肾衰竭患者或接受血液透析和/或接受抗凝治疗的患者的组织钙化的方法。本发明进一步提供了用于减轻慢性阻塞性肺病（COPD）的一种或多种症状的方法和组合物，包括使用甲萘醌-7（MK-7）和/或甲萘醌醇-7（MKH2-7），用于预防或治疗（例如，减缓慢性阻塞性肺病的进展、阻止和/或逆转）慢性阻塞性肺病的一种或多种症状。
• Leal, J. M.; Arcos, J.; Garcia, B., Zeitschrift fur Physikalische Chemie (Leipzig), 1989, vol. 270, # 5, p. 887 - 896
  作者：Leal, J. M.、Arcos, J.、Garcia, B.

  DOI：——

  日期：——
• METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING TISSUE CALCIFICATION
  申请人：Epizon Pharma, Inc.

  公开号：US20210093584A1

  公开（公告）日：2021-04-01

  The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.